Cellmid Limited [ASX:CDY] share price and news 2022

Company Description

Cellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company holds global intellectual properties relating to novel targets midkine and FGF5.

Cellmid Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.cellmid.com.au.

This a small cap company with market cap of 11 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while Company PB is less than both sector and market. On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 1.25 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how cdy dividend grows in the recent years.

No data